AI assistant
COGSTATE LTD — Regulatory Filings 2007
Jul 8, 2007
64644_rns_2007-07-08_9defc8f4-005f-4e7c-a6cc-b6cfeed1a009.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
CogState Ltd ABN 80 090 975 723
==> picture [235 x 49] intentionally omitted <==
Level 7 21 Victoria Street Melbourne Vic 3000 Australia
ASX Announcement
Melbourne, 09 July 2007
CogState Signs Second Agreement with Merck & Co., Inc.
CogState Ltd (ASX:CGS) announced today that it is has signed a second contract with global research-driven pharmaceutical company, Merck & Co., Inc. for the use of CogState’s cognitive testing technology and associated services in a clinical trial due to start this year.
Mr. Brad O’Connor, chief executive officer of CogState, said, “As one of the largest pharmaceutical companies in the world, with an extensive CNS portfolio, Merck is a valued customer of CogState. This second contract is evidence of the strengthening relationship between the companies.”
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Organon USA and GlaxoSmithKline. CogState is currently expanding its existing activities in the U.S. clinical trial markets.
For additional information:
Brad O’Connor Chief Executive Officer CogState Ltd. Ph: 03 9664 1300 or 0411 888 347 [email protected]
Page 1 of 1